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ABSTRACT 
 
 
Aims  To describe the numbers and costs of medications  prescribed to people 
living with diabetes resident in nursing homes in one Primary Care Trust (PCT) in 
the UK 
 
Methods   A retrospective case notes review of 75 people with known diabetes 
who were resident in the 11 Nursing homes in  Coventry Teaching PCT     
 
Results  63 residents (84%) were being prescribed 4 or more medications. 
44 residents (59%) were  prescribed antiplatelet drugs for CVD prevention 
including aspirin, clopidogrel and dipyridamole and 31 residents (41%) were  on 
statin therapy.  
18 (24%)  residents had a monthly medication cost  that was above £101 per 
month. On detailed review these were largely residents who were being 
prescribed special order liquid preparations, usually for secondary CVD 
prevention. 
 
Conclusion  . Polypharmacy, defined as taking 4 or more drugs per day per 
resident is highly prevalent within this population of care home residents with 
diabetes. 
 A high proportion of residents are prescribed drugs for cardiovascular disease 
prevention which may be entirely inappropriate in this  population  with limited life 
expectancy.. 
Regular medication review of care home residents with diabetes should be  
undertaken   as it has the potential to reduce costs, minimise adverse drug 
reactions, and increase health gain.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Polypharmacy does not have a formally accepted definition but it is usually 
considered as concurrent prescribing of at least four or five drugs (1). In one 
German study , over a quarter of older patients in primary care were found to be 
on five or more medications. (2)  
Polypharmacy  can also be considered as inappropriate medication use, is a 
significant problem in older patients who have more chronic co-morbid conditions 
and are more likely to experience adverse drug side effects, than younger 
populations (3) The problem of polypharmacy and inappropriate medication is 
correlated with age, co-morbidity, disability, and the number of medications (4) . 
It increases the likelihood of nursing home placement, impaired mobility, 
morbidity, hospitalization and death (4).  
Therapies are often prescribed for older people based on evidence from studies 
of younger people who usually have few co-morbidities and who have life 
expectancies of several decades. Applying the results and/or the clinical 
guidelines developed from these studies, to elderly people may be inappropriate 
because of higher risk to benefit ratios with increasing age, complexity of illness,  
and number of medications prescribed (3,5) 
Medicines cost the NHS in excess of £10 billion annually with the total cost and 
number of prescriptions is steadily rising. In this current time of national financial 
austerity it is important to ensure that prescribing is effective in maximising health 
gains, ensuring high levels of cost-effectiveness and minimising risks to patients. 
(1)  
A study  has been published which suggests that elderly people with diabetes 
living in Care homes in France are being over- medicated (6). A study from 
Sweden has suggested that diabetes medications can be safely reduced or 
withdrawn in some nursing home patients (7) . There has been little information 
published in this area from the UK, apart from some case history reports of over 
medication producing hypoglycaemia (8,9)  
An initial paper describing the significant levels of disability and nursing need in 
people with diabetes living in Nursing homes in Coventry has already been 
published (10). This report describes the medications prescribed and the costs of 
the medications in these residents. 
 
Methods 
Permission to perform this study was obtained from Coventry PCT and the 
Warwickshire  Biomedical Research Ethics Committee 
The data was collected from a retrospective case notes review of the 75 people 
with known diabetes who were resident in the 11 Nursing homes in the Coventry 
Teaching PCT in early 2010.    
The researcher (RG) visited each of the 11 homes during February to April 2010. 
Data on the total number of residents in each home and the total with known 
diabetes were obtained at the visit from the manager or senior nurse on duty. 
The notes of everyone with known diabetes were then reviewed. Information on   
co-morbidities, disabilities and current regular medications was extracted. 
Data were recorded and analysed on an Excel spreadsheet. (8) The cost of the 
medications were calculated by MG and the Coventry Medicines Management 
Team using costings from the BNF of March 2010 for tablets and actual costs 
from pharmacies for special order liquid medications. 
The last recorded HBA1c result for each resident was obtained from the local 
hospital laboratory database  
 
Results 
Numbers of Medications 
The 75 Nursing home residents in the study had an age range of 55 -102 years 
(mean age 80.6years) . They were being prescribed a mean of  6.7 (range 0 -17) 
individual regular medications either orally or parenterally . All “as required” 
medications, and all local treatments (e.g  creams, eye drops etc ) have been 
excluded from this analysis. One resident, aged 102 years, had refused to take 
any medications for the past 3 years and so was recorded as taking none. The 
number of residents taking different numbers of medications are listed in table 1 
 
Table 1 
Number of 
medications 
per  day  
0-3 4-7 8-11 12 + 
Number of 
Residents 
12 34 26 3 
 
 
Significant numbers of residents were being prescribed primary and secondary 
CVD prevention therapies and these are listed in Table 2 
 
TABLE 2 
Primary & Secondary CVD prevention therapies 
 
MEDICATION NUMBER OF RESIDENTS ( n=75) 
Aspirin 34 
Dipyridamole 4 
clopridogrel 6 
Anti-hypertensives 42 
Statins 31 
 
An HBA1c measurement recorded in the previous 12 months was available for 
69 residents (92%) from the local hospital laboratory database. 
The glucose lowering medications being prescribed for the residents are listed in 
table 3 along with the mean HBA1c level and range  
 
 
 
 
 
TABLE 3 – Glucose Lowering Therapies & HBA1c Results 
Glucose lowering 
therapy 
Number of 
residents (n=75) 
Mean HBA1c and 
range in 
% and IFCC units 
Number of 
residents with 
HBA1c 
measurement 
within previous 
year n=69 
Diet alone 20 6 (5.4-6.7) 
42 (35-50) 
16 
Metformin 
monotherapy 
19 7 (4.9-8.8) 
53 (30-73) 
18 
Gliclazide 
monotherapy 
11 6.8 (5.4-12.3) 
51 (35-111) 
10 
Two or more oral 
agents 
6 5.8 (4.6-6.9) 
40 (27-52) 
6 
Insulin alone 16 7.1 (6.1-10.5) 
54 (43 -91) 
16 
Insulin plus oral 
agent 
3 8.8 (7.7-10.2) 
73 (61-88) 
3 
 
 
Total Medication costs 
The mean monthly prescription cost for the 75 residents (one of whom was on no 
medications) based on BNF from March 2010  was £90-88p (range 0- £799)  
Table  4 lists the numbers of residents by prescription costs per month per 
resident 
Table  4 
Medication 
costs per 
month 
0to £20 £21 to £100 £101to £300 £301 and 
more 
Number of 
residents 
n=75 
24 33 10 8 
 
The costs of nutrition therapies for the 14 residents on PEG feeding have not 
been included. The average price of these has been calculated to be around 
£200/month per resident  based on nutrison  2 Litres per day. 
 
There were 18 (out of the 75)  residents whose monthly medication cost was 
above £101 per month. On detailed review these were largely residents who 
were being prescribed special order liquid preparations, usually for secondary 
CVD prevention. The costs of such liquid formulations are often around 30 to 50 
times that of standard oral tablets. For example the cost of bisoprolol 5mg tablet 
one daily is £5-90 per month whereas the costing of bisoprolol liquid at the same 
dose is £315 per month.  Simvastatin 40mg tablet once daily is costed at £1-52 
per month whereas simvastatin liquid is £152 per month for the same dose. The 
total monthly cost of the 8 people with prescriptions over £301 per month is 
£3162 per month which is 47% of the total monthly cost of the 75 residents in this 
study. The total monthly cost of the 18 people with prescriptions over £101 per 
month is £3877 which is 72.5% of the total monthly cost of the 75 residents in the 
study 
 
Costs of Glucose Lowering Medications 
Most residents on oral glucose lowering therapies were on either metformin or 
gliclazide monotherapy which are generic drugs costed at around £1-50 per 
month. Several of the residents on insulin were being prescribed under 20 
units/day so these were costed at below £20 per month. The two residents who 
had glucose lowering therapy costs of over £101 per month were being 
prescribed special order gliclazide liquid which was costed at £100 per month as 
compared with £1-24 per month for Gliclazide 80mg tablets twice a day 
 
Discussion 
If  polypharmacy is defined  as being the concurrent prescribing of four or more 
drugs  63   residents ( 84 %) in this study meet the criteria of polypharmacy.  44 
residents (59%) were being prescribed antiplatelet drugs for CVD prevention 
including aspirin, clopidogrel and dipyridamole and 31 residents (41%) were on 
statin therapy. Given the levels of disability and nursing need described in this 
group of residents in our earlier paper (10) it could be concluded that  CVD 
prevention therapy is inappropriate  and is unlikely to have any benefit in 
prolonging or enhancing remaining life.  By increasing the risk of adverse drug 
effects it might well be causing a reduction in quality of any remaining life.  More 
than one third of the residents were being prescribed 8 or more medications per 
month. This group might be considered to be most at risk from the dangers of 
polypharmacy and could be the group who should be targeted and prioritised to 
see if any medications could be usefully stopped. 
Glucose lowering medications do not seem to be a cost driver in this group of 
residents as the majority are being prescribed cheap generic oral agents. The 
only exceptions were 2 residents who were being prescribed gliclazide in a liquid 
formulation costed at £100 per month per resident. 
 HBA1c results in these residents indicate that many have  levels well below 7%. 
Through medication review and discussion between the prescriber, nursing home 
staff, and the resident (wherever this is possible) reductions in prescribed 
glucose lowering therapies may be beneficial, to reduce the risk of 
hypoglycaemia, in a population of residents likely to have multiple risk factors for 
hypoglycaemia (9). 
 There may be some possibility of improving the quality of life of the 19 residents 
(25%)  prescribed insulin by reducing the number of injections given  per day, 
through altering the insulin prescription.  Two people were being prescribed basal 
insulin plus short acting insulin and 11 were being prescribed twice daily mixed 
insulin. It might be possible at a medicines review to consider changing these to 
a once daily long acting basal insulin.   
It therefore seems that the main driver of medication costs in this study is the 
prescription of very expensive liquid preparations in residents,  presumably who 
have been deemed to have  swallowing difficulties or who were being PEG fed. 
On review it is possible that these expensive medications might be able to be 
stopped after discussion between the prescriber, the nursing home staff and the 
resident (if this is possible)  when they are felt to be no longer of clinical benefit. If 
continuing these prescriptions is thought to be best the substitution of tablet 
medication, which could then be crushed,  would  give  considerable financial 
saving. In our opinion it is not unreasonable to suggest that with appropriate 
medication review and discussion, medication changes resulting in at least a 
50% reduction in the prescription costs for this group of residents would be 
possible. This would result in yearly savings of around £40,000 based on this 
study population. The 11 Nursing homes in Coventry are likely to be typical and 
representative of other  nursing homes in England. If similar savings were able to 
be replicated across England the cost savings would be in the region £10 to 12 
million pounds, a not insignificant sum in these times of financial restriction. 
Although we did not study the prevalence of adverse drug reactions in these 
residents, medication review leading to the prescription of fewer and more 
appropriate medications might also result in benefits relating to quality of life and 
well-being in this vulnerable group of residents.  
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